2013 News

Vascular BioSciences Will Present Results of “CAR Peptide Targeted Liposomes Loaded with an Admixture of Fasudil and DETA Nonoate for the Treatment of PAH”, and “A PAH Drug Ranking Strategy for Individualized Combination Therapy via Pulmonary Endoarterial Biopsy” at the Ameri

Vascular BioSciences Announces Publication of “Intratracheally Administered Peptide-Modified Lipid Admixture Containing Fasudil and/or DETA NONOate Ameliorates Various Pathologies of Pulmonary Arterial Hypertension” Vascular BioSciences Announces Publication of Promising Preclinical Resu

Vascular BioSciences Announces Publication of “A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy” in the Current Issue of The Open Respiratory Medicine Journal  Vascular BioSciences Announces Publication of “A Bioinformatic Alg

Vascular BioSciences Announces Publication of “CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension” in the Current Issue of The Open Respiratory Medicine Journal Vascular BioSciences Announces Publication of “C

Vascular BioSciences Receives $2.7M STTR Fast-Track Grant for CAR Liposomes with VA Hospital of Northern California Vascular BioSciences will be collaborating with the VA Hospital of Northern California on the development of CAR liposomes for pulmonary arterial hypertension treatment GOLETA, CA — Va

Vascular BioSciences Announces New Preclinical Research Results Demonstrating Improved Pulmonary Hypertension and Sepsis Survival with CAR Peptide CEO of Vascular BioSciences, David Mann, makes connection between current research and COVID-19 applications Goleta, CA – Vascular BioSciences announces

FDA Grants Vascular BioSciences Humanitarian Use Device (HUD) Designation to the Endoarterial Biopsy Catheter for Group 1 Pulmonary Arterial Hypertension Humanitarian Use Device (HUD) designation from the U.S. Food and Drug Administration (FDA) for the Endoarterial Biopsy Catheter (EABC) to take pul

Vascular BioSciences Presented Results of CAR Peptide Targeted Augmentation of Chronic Prostanoid Treatment in PAH at the ATS Meeting in Dallas, Texas New data on beneficial effects of co-administration of CAR peptide with treprostinil in experimental pulmonary hypertension GOLETA — Vascular BioScie

Vascular BioSciences Awarded $2 Million Phase II STTR Grant From NHLBI to Develop CAR Peptide as a Targeted Therapy for Pulmonary Hypertension Grant awarded in partnership with Brigham and Women’s Hospital, Harvard Medical School Durham, North Carolina – Vascular BioSciences (VBS) is proud to

Vascular BioSciences Awarded Up To $2.3 Million Fast-Track STTR Grant From NHLBI To Develop CAR Peptide For Pulmonary Hypertension Project to be Conducted in Collaboration with Brigham and Women’s Hospital, Harvard Medical School. Durham, North Carolina, August 15th, 2017 – Vascular BioSciences anno

Vascular BioSciences Announces Publication of “Assessment of microRNA and gene dysregulaton in pulmonary hypertension by endoarterial biopsy” in the Current Issue of Pulmonary Circulation Goleta, CA., May 19, 2017 – Vascular BioSciences announces publication of “Assessment of microRNA and gene

Vascular BioSciences announces publication of “Challenges in the development of chronic pulmonary hypertension models in large animals” in the Current Issue of Pulmonary Circulation Goleta, CA., February 1, 2017 – Vascular BioSciences announces publication of “Challenges in the development of

Vascular BioSciences’ Sepsis Research Wins Award at the 46th Annual Critical Care Congress of the Society of Critical Care Medicine Hydrocortisone Therapy with CAR Peptide Protects the Injured Endothelial Glycocalyx in Sepsis. Honolulu, HI, January 22, 2017 – On January 22, 2017, Dr. Kod

Vascular BioSciences congratulates VP of Communications, Dr. Susana Peinado, Ph.D., on being awarded her Doctorate from UCSB School of Communication Goleta, Ca, June 7, 2016 — Vascular BioSciences announced today that Dr. Susana Peinado, Ph.D., Vice President of Communications at Vascular BioScience

Vascular BioSciences to Make Six Presentations at the American Thoracic Society in San Francisco from May 15 – May 18 Vascular BioSciences to present the full scope of its research efforts at this year’s ATS International ConferenceGoleta, CA, May 12, 2016 – Vascular BioSciences announces that it wi

Vascular BioSciences Named the 2015 Winner of the Buzz of Bio “Pipelines of Promise” Competition Goleta, CA, May 21, 2015 – On April 30, 2015, the Biotech International Organization (BIO) announced Vascular BioSciences (VBS) as the winner of its Buzz of BIO competition in the “Pipelines of Pro

The American Journal of Pathology Highlights “CAR Selectively Enhances Drug Efficacy in PAH” as a Featured Article in the February 2014 Issue Goleta, CA, February 5, 2014 – The American Journal of Pathology announced in a press release that a peer-reviewed scientific article about Vascular BioScienc

Vascular BioSciences Announces Online Publication of Scientific Article Describing First Orally Available Disease Homing Peptide That Can Selectively Enhance the Effects of Co-Administered Drugs Goleta, CA, January 6, 2014 – Vascular BioSciences announces the e-publication of “A Novel Vascular

Vascular BioSciences Awarded $1.2 Million Contract from the NHLBI’s Vascular Interventions/Innovations and Therapeutic Advances (VITA) Program to Develop CAR Peptide Therapeutic Adjuvant for PAH Targeted Therapy Durham, NC – Vascular BioSciences (VBS) announced the award of a $1.2 million, milestone

Vascular BioSciences announces publication of “Vascular Histomolecular Analysis By Sequential Endoarterial Biopsy in a Shunt Model of Pulmonary Hypertension” in the Current Issue of Pulmonary Circulation Goleta, CA., April 10, 2013 – Vascular BioSciences announces the publication of “Vascular Histom

Vascular BioSciences recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to develop the CAR peptide as a therapeutic adjuvant. Goleta, CA., October 11, 2012 – Vascular BioSciences recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to develop the CAR p

Vascular BioSciences announces CEO David Mann will present “CAR Peptide, a Disease Selective Therapeutic Adjuvant For Targeted Drug Therapy” during the 7th Annual Therapeutic Peptide Symposium San Diego, CA., October 10, 2012 – Vascular BioSciences announces CEO David Mann will present “CAR Peptide,

Vascular BioSciences announced today that Dr. Kalju Kahn, PhD, has been named head of Medicinal Chemistry Goleta, Calif., July 3, 2012 – Vascular BioSciences announced today that Dr. Kalju Kahn, PhD, has been named head of Medicinal Chemistry. Dr. Kahn, an expert in computational chemistry and drug

Vascular Biosciences announces publication of “Hemodynamic and Histologic Characterization of a Swine (Sus scrofa domestica) Model of Chronic Pulmonary Arterial Hypertension” Durnham, North Carolina, June 27, 2011 – Vascular BioSciences announces the publication of a scientific article which describ

Peptide-Directed Highly Selective Targeting of Pulmonary Arterial Hypertension” Selected by Faculty of 1000 Goleta, Calif., June 24, 2011 – A recently published paper from Vascular BioSciences (VBS) in collaboration with Sanford-Burnham Medical Research Institute and the University of South Alabama

VBS Pharmaceuticals announces publication of “Peptide-Directed Highly Selective Targeting of Pulmonary Arterial Hypertension” Goleta, Calif., June 10, 2011 – VBS Pharmaceuticals, in collaboration with the Sanford-Burnham Medical Research Institute, and the University of South Alabama, announces the

David Mann, CEO of Vascular BioSciences, Presents Opening Remarks at the Southern California Undergraduate Research Conference in Chemistry and Biochemistry (SCURC) Santa Barbara, Calif., April 24, 2011 – Opening speaker David Mann presented the following remarks at the SCURC at the University of Ca

Vascular BioSciences to Sponsor 2011 Southern California Undergraduate Research Conference in Chemistry and Biochemistry Santa Barbara, Calif., April 23, 2011 – Vascular BioSciences will be a major sponsor of the 2011 Southern California Undergraduate Research Conference in Chemistry and Biochemistr

Vascular BioSciences, In Collaboration with the University of South Alabama, Awarded Exploration/Development R21 Grant from the National Heart Lung Blood Institute of the National Institutes of Health for Cell-targeted Drug Delivery for the Treatment of Pulmonary Arterial Hypertension (PAH) Durham,

Vascular BioSciences Awarded Qualifying Therapeutic Discovery Project Grant to Develop CAR Peptide as a Therapeutic Adjuvant San Diego, CA, November 9, 2010 – Vascular BioSciences was awarded a grant in the amount of $181,876 from the U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP)

Vascular BioSciences Opens New Office and Pilot Catheter Manufacturing Facility in Goleta, California Goleta, Calif., January 8, 2010 – Vascular BioSciences announced today that it has opened a new office and pilot catheter manufacturing facility in Goleta, California. The new Goleta office will als

Vascular BioSciences CEO David Mann Awarded New U.S. and European Patents for Endorterial Biopsy Catheterization Equipment Kit Invention San Diego, CA, February 18, 2009 – Vascular BioSciences announced today that it was awarded US Patent No. 7,491,176 titled “A Kit for Obtaining an Endoarterial Bio

Abraham Rothman, M.D. to Present “Pulmonary Endoarterial Biopsy” at the Society for Cardiovascular Angiography and Interventions at the American College of Cardiology Annual Innovation in Intervention Meeting in Chicago, Illinois Chicago, Illinois, March 28, 2008 – Vascular BioSciences announced tod

Vascular BioSciences Awarded STTR Matching Grant from the State of North Carolina Durham, North Carolina, March 26, 2008 – Vascular BioSciences announced today it has been awarded a $100,000 STTR matching grant under the One North Carolina SBIR/STTR Matching Funds Program. The One North Carolina SBI

Vascular BioSciences Awarded Phase 1 STTR Grant from the National Heart Lung Blood Institute of the National Institutes of Health for Pulmonary Hypertension Durham, North Carolina, February 1, 2008 – Vascular BioSciences announced today it has received a STTR Phase 1 grant from the National Heart Lu

Vascular BioSciences Moves Research and Development to North Carolina Durham, North Carolina, January 24, 2008 – Vascular BioSciences announced today that it has opened an office in Research Triangle, North Carolina that will be the principal location of the company’s research and development effort

Vascular BioSciences Announces Key Addition to Molecular Diagnostics Team: Dr. Roy Williams of Burnham Institute Brings Bioinformatics Expertise San Diego, Calif., October 12, 2007 – Vascular BioSciences announced today that Dr. Roy Williams, Ph.D., will join the company as a Special Consultant for

Vascular BioSciences Extends Patent Portfolio: Signs Exclusive IP License Agreement with the Burnham Institute for Medical Research San Diego, Calif., February 28, 2007 – Vascular BioSciences announced today that it has secured a worldwide exclusive license to intellectual property from Burnham Inst

Vascular BioSciences announces a Cooperative Research And Development Agreement with the U.S. Army Institute of Surgical Research to Develop Diagnostic and Therapeutic Solutions Addressing Acute Respiratory Distress Syndrome Secondary to Battlefield Trauma San Diego, Calif., February 17, 2006 – Vasc

VBS Congratulates Erkki Ruoslahti, M.D., Ph.D., on Receiving the 2005 Japan Prize in Cell Biology in Tokyo, Japan San Diego, Calif., April 20, 2005 – Vascular BioSciences (www.vascularbiosciences.com) announced today that Erkki Ruoslahti, M.D., Ph.D., a member of Vascular BioSciences’ (www.vascularb

VBS announces that Erkki Ruoslahti, MD, PhD, joins its Board of Advisors San Diego, Calif., December 3, 2003 – Vascular BioSciences (www.vascularbiosciences.com) announced today that Erkki Ruoslahti, M.D., Ph.D. will join its Board of Advisors. “We are honored that a physician and scientist of Erkki

VBS Announces Lung Transplant Rejection Detection with the Endoarterial Biopsy Catheter in an Animal Model San Diego, Calif., April 15, 2003 – Vascular BioSciences (www.vascularbiosciences.com) announces the publication of a new method to detect lung transplant rejection using the company’s endoarte